CTOs on the Move

Mustang Bio

www.mustangbio.com

 
Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.mustangbio.com
  • 2 Gansevoort Street 9th Floor
    New York, NY USA 10014
  • Phone: 781.652.4500

Executives

Name Title Contact Details
Knut Niss
Chief Technology Officer Profile

Funding

Mustang Bio raised $20M on 04/01/2019
Mustang Bio raised $75M on 03/08/2022

Similar Companies

Design Therapeutics

Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions.

PharmaDerm

PharmaDerm is a Florham Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Astellas

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms - Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category leader in oncology. At all levels throughout the company our people are committed to the opportunity to positively affect and improve patient lives while remaining socially responsible to our community and those with whom we work and collaborate.

Prescription Solutions by OptumRx

Prescription Solutions is an innovative pharmacy benefit management company managing the prescription drug benefit of commercial, Medicare and other governmental health plans, as well as those of employers and unions. A UnitedHealth Group company,

Promentis Pharmaceuticals

Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.